CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Tissue Regenix Group PLC is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Tissue Regenix Group PLC
Unit 3
Phoenix Court, Lotherton Way, Garforth
Phone: +44 1904567609p:+44 1904567609 LEEDS, LS25 2GY  United Kingdom Ticker: TRXTRX
Business Summary
Tissue Regenix Group plc is a medical device company in regenerative medicine. The principal activity of the Company is the exploitation of platform technologies in the field of bone graft substitutes and soft tissue. It is focused on the development of regenerative products utilizing its two platform technologies, dCELL, addressing soft tissue needs, and BioRinse, providing sterile bone allografts. Its divisions include dCELL, BioRinse and GBM-V. The Company's patented decellularization technology (dCELL) removes DNA and other cellular material from animal and human soft tissue, leaving an acellular tissue scaffold not rejected by the patient's body that can be used to repair diseased or damaged body structures. Its proprietary BioRinse technology platform is primarily utilized to provide sterile tissue prepared in a manner to minimize the negative effects of processing. GBM-V produces tissue preparations for ophthalmology, primarily cornea, using conventional, classical methods.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202312/31/2023Yes---Yes

Industries
SIC Code Description
7372 Prepackaged software
7389 Business services, not elsewhere classified
2836 Biological products, except diagnostic substances
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Non-Executive Chairman of the Board Jonathan M.Glenn 55 2/26/2021 1/19/2016
Chief Executive Officer, Executive Director Daniel R.Lee 67 11/16/2020 11/16/2020
Chief Financial Officer, Executive Director David C.Cocke 68 1/21/2021 1/21/2021
9 additional Officers and Directors records available in full report.

Business Names
Business Name
CellRight Technologies LLC
Tissue Regenix Limited
Tissue Regenix Wound Care Inc.
6 additional Business Names available in full report.

General Information
Number of Employees: 76 (As of 12/31/2023)
Outstanding Shares: 70,574,468 (As of 12/31/2023)
Stock Exchange: LON
Fax Number: +44 1904380517


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, April 24, 2024